Hepatitis B Singapore Clinic

Hepatitis B Singapore Clinic: Hepatits B - symptoms in men/women, screening/diagnosis, testing/check, treatment clinic, Singapore - Private and confidential service. Definitions, references, and latest news.

Description

Hepatitis B infection is caused by the Hepatitis B virus and is usually screened for by detecting HBsAg in the blood. Immunity may be discerned by detecting HBsAb, and if absent, Hepatitis B vaccination may be done.

• The hepatitis B virus is 100 times more infectious than HIV, the virus that causes AIDS, and infects about 10 times more people than HIV worldwide.
• Hepatitis B virus infects the liver, and more than 350 million people in the world are lifelong hepatitis B virus carriers.
• Long-term hepatitis B virus infection causes at least one million premature deaths every year from cirrhosis of the liver or liver cancer. It is second only to tobacco as the leading cause of cancer in humans.
• Among the Hepatitis B carriers, 25% will develop serious liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
• The hepatitis B virus can be passed from an infected mother to her baby during childbirth, 1 in 20 Singaporeans are chronically infected with hepatitis B virus.

Treatment

• Nucleoside analog reverse transcriptase inhibitors
  • Lamivudine (Epivir) - 40% resistance by 2 years. Also used to treat HIV
  • Telbivudine (Tyzeka)
  • Entecavir (Baraclude)
• Nucleotide analog reverse transcriptase inhibitors
  • Adefovir (Hepsera)
  • Tenofovir (Viread) - Also used to treat HIV

References

• Hepatitis B - Wikipedia, the free encyclopedia
• Hepatitis B: Definition from Answers.com
• Hepatitis B - definition of Hepatitis B in the Medical dictionary - by the Free Online Medical Dictionary, Thesaurus and Encyclopedia.
• WHO | Hepatitis B
• CDC Division of Viral Hepatitis - Hepatitis B Public/HP Pages Choice
• HON: Hepatitis B - Virology and Immunology

Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation
Tue, 27 Jul 2010 23:00:00 +0100 | NeLM - Drug Specific Reviews
Source: Cochrane Library Area: Evidence > Drug Specific Reviews Background Recurrence of hepatitis B virus (HBV) infection in the liver graft is a grave complication following liver transplantation for HBV cirrhosis. Hepatitis B immunoglobulin (HBIg) seems effective in increasing survival after liver transplantation. HBIg and anti-viral drugs are given alone or in combination for its prevention.   Objectives To assess the benefits and harms of different regimens for preventing HBV reactivation following liver transplantation.   Search strategy We searched The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, EMBASE, and Science Citation Index Expanded until ...

Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B
Tue, 27 Jul 2010 09:11:54 +0100 | Inflammation Research
Conclusions  These results suggest that over-expression of PD-1, PD-L1 and PD-L2 within liver may participate in local immune dysfunction, which could be one of the mechanisms involved in the chronicity of HBV infection and chronic inflammation seen in CHB patients. Content Type Journal ArticleCategory Original Research PaperDOI 10.1007/s00011-010-0233-1Authors Ji Chen, Peking University First Hospital Department of Infectious Diseases No. 8, Xishiku Street, Xicheng District Beijing 100034 People’s Republic of ChinaXiao-Mei Wang, Beijing Ditan Hospital Department of Pathology No. 8, Jingshun East Road, Chaoyang District Beijing 100015 People’s Republic of ChinaXue-Jie Wu, Peking University First Hospital Department of Infectious Diseases No. 8, Xishiku Street, Xic...

2010 Annual Evidence Update on Hepatitis B and C - Introduction
Tue, 27 Jul 2010 05:46:26 +0100 | Gastroenterology and Liver Diseases Specialist Library - Liver
NHS Evidence Annual Evidence Updates (AEUs) attempt to draw together recently published, high quality evidence – focusing particularly on systematic reviews and published guidelines - which it is hoped will inform and enhance the decision making and planning of clinicians, commissioners and others involved in the process of health care. For this Hepatitis B and C AEU updating last year's work, a detailed literature search from 2009-2010 identified 246 potential pieces of evidence (see methods for retrieving and evaluating the evidence for more information). Following a process of filtering and peer review (with thanks to the reviewers listed below) 61 of these form the basis of this AEU. It is imperative that those involved in commissioning and delivering care are apprised of the best av...

Inhaled plus systemic steroid treatment linked to HBV reactivation
Tue, 27 Jul 2010 00:00:00 +0100 | MedWire News - Respiratory
Results from a South Korean study suggest that the addition of systemic corticosteroids to inhaled corticosteroid treatment in patients with asthma or chronic obstructive pulmonary disease is associated with an increased risk for hepatitis B virus reactivation. (Source: MedWire News - Respiratory)

A study on the association with hepatitis B and hepatitis C in 1557 patients with lichen planus
Mon, 26 Jul 2010 23:00:00 +0100 | Journal of the European Academy of Dermatology and Venereology
Conclusion Lichen planus is associated with hepatitis C but not with hepatitis B. Physicians who care for patients with lichen planus should consider screening patients with lichen planus for hepatitis C. (Source: Journal of the European Academy of Dermatology and Venereology)

Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B
Mon, 26 Jul 2010 23:00:00 +0100 | Journal of Viral Hepatitis
Summary. The prognostic value of liver stiffness measurements for chronic hepatitis B (CHB) is not known. The present study aimed to investigate the use of transient elastography in predicting hepatocellular carcinoma (HCC) development and mortality in patients with CHB. Five hundred and twenty-eight patients with HBeAg-negative CHB underwent liver stiffness measurements and were prospectively followed up every 3[ndash]6 months for a median length of 35 months. The patients were divided into those with liver stiffness (Source: Journal of Viral Hepatitis)

UCLA launches first West Coast human hand transplantation program
Mon, 26 Jul 2010 18:30:00 +0100 | UCLA Newsroom: Health Sciences
(Note to editors: DVDs with soundbites and animation are available through media officers.)   The UCLA Health System has launched the new UCLA Hand Transplantation Program, the first of its kind on the West Coast and only the fourth such center in the United States.   The program will help those who have suffered the traumatic loss of a hand or forearm and allow them to regain function and improve their quality of life. Qualified candidates are now being sought for a clinical study of the procedure.    "Over the past decade, the exciting field of hand transplantation has resulted in excellent outcomes for patients, and we are excited to bring this program to UCLA," said Dr. Kodi Azari, surgical director of the hand transplantation program and an associate professor in t...

Use of Gloves and Reduction of Risk of Injury Caused by Needles or Sharp Medical Devices in Healthcare Workers: Results from a Case‐Crossover Study
Mon, 26 Jul 2010 16:28:56 +0100 | Infect Control Hosp Epidemiol Latest Issue
Conclusions. Although the use of gloves reduces the risk of sharps injuries in health care, use among healthcare workers is inconsistent and may be influenced by risk perception and healthcare culture. Glove use should be emphasized as a key element of multimodal sharps‐injury reduction programs. (Source: Infect Control Hosp Epidemiol Latest Issue)

A randomised controlled trial of computer-assisted interviewing in sexual health clinics
Mon, 26 Jul 2010 14:48:51 +0100 | Sexually Transmitted Infections
Conclusion CASI and CAPI can generate greater recording of risky behaviour than traditional PAPI. Increased disclosure did not increase STI diagnoses. Safeguards may be needed to ensure that clinicians are prompted to act upon disclosures made during self-interview. Trial registration ISRCTN: 97674664. (Source: Sexually Transmitted Infections)